PTEN and neoplasm: The role of PTEN in predicting resistance to anti-EGFR MoAbs was confirmed by Sartore-Bianchi and colleagues, who found that loss of PTEN protein was associated with lack of response to cetuximab and panitumumab (p = 0.001) in a cohort of 81 tumor specimens.